Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020832 | 0.87 | GAA (0.46) | KDM4ELOXL2FFAR1METAP2CHRNA7 | |
| SCHEMBL1111547 | 0.87 | GAA (0.46) | KDM4ELOXL2FFAR1METAP2CHRNA7 | |
| Hydrochloric Acid SCHEMBL1111607 | 0.87 | GAA (0.46) | KDM4ELOXL2FFAR1METAP2CHRNA7 | |
| SCHEMBL19753215 | 0.74 | CYP2A6 (0.53) | KDM4ECHRNA7KCNH2CRHBPCRHR2 | |
| SCHEMBL13640532 | 0.72 | LOX (0.31) | LOXL2CHRNA7 | |
| SCHEMBL28132432 | 0.72 | LOXL2 (0.50) | KDM4ELOXL2 | |
| SCHEMBL21959783 | 0.70 | KDM4E (0.60) | KDM4ELOXL2CHRNA7KCNH2GAA | |
| SCHEMBL745692 | 0.70 | CYP19A1 (0.47) | KDM4EMETAP2CHRNA7KCNH2CRHBP | |
| SCHEMBL2005505 | 0.70 | FLT3 (0.50) | KDM4EGAA | |
| SCHEMBL13640514 | 0.70 | CACNA1H (0.41) | KDM4EMETAP2CHRNA7GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | CHRNA7, CHRNA5, CHRNA1 | KDM4E 1262/4885LOXL2 4276/4885FFAR1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.